Видео ютуба по тегу Undetectable Mrd

Undetectable MRD after obinutuzumab plus venetoclax in CLL
Undetectable MRD after obinutuzumab plus venetoclax in CLL
TOURMALINE-MM3: undetectable MRD as an endpoint for maintenance therapy
TOURMALINE-MM3: undetectable MRD as an endpoint for maintenance therapy
AVO achieves high rates of undetectable MRD in CLL
AVO achieves high rates of undetectable MRD in CLL
Achieving undetectable MRD with ibrutinib plus venetoclax for CLL
Achieving undetectable MRD with ibrutinib plus venetoclax for CLL
Post-induction undetectable MRD ameliorates the high risk determined by FISH among NDMM
Post-induction undetectable MRD ameliorates the high risk determined by FISH among NDMM
The impact of sustained undetectable MRD on survival in patients with myeloma treated with ide-cel
The impact of sustained undetectable MRD on survival in patients with myeloma treated with ide-cel
ASH CLL highlights: ibrutinib-venetoclax combination & undetectable MRD in IGHV-mutated patients
ASH CLL highlights: ibrutinib-venetoclax combination & undetectable MRD in IGHV-mutated patients
GEM-CESAR trial: post-hoc analysis of sustained undetectable MRD in patients with high-risk SMM
GEM-CESAR trial: post-hoc analysis of sustained undetectable MRD in patients with high-risk SMM
Undetectable Measurable Residual Disease in CLL / SLL - Dr. Tilal Hilal
Undetectable Measurable Residual Disease in CLL / SLL - Dr. Tilal Hilal
Pros and cons of MRD testing in CLL
Pros and cons of MRD testing in CLL
Driver mutations predicting clinical outcomes upon MRD-guided venetoclax plus ibrutinib in R/R CLL
Driver mutations predicting clinical outcomes upon MRD-guided venetoclax plus ibrutinib in R/R CLL
What Does Minimal Residual Disease (MRD) Mean for CLL Patients?
What Does Minimal Residual Disease (MRD) Mean for CLL Patients?
Dr Burke on MRD Testing in CLL and Myeloma
Dr Burke on MRD Testing in CLL and Myeloma
Predicting MRD outcomes in myeloma using machine learning
Predicting MRD outcomes in myeloma using machine learning
Ven-based regimens for R/R CLL and considering an MRD-guided strategy
Ven-based regimens for R/R CLL and considering an MRD-guided strategy
Undetectable Measurable (Minimal) Residual Disease in Chronic Lymphocytic Leukemia - ASH 2021
Undetectable Measurable (Minimal) Residual Disease in Chronic Lymphocytic Leukemia - ASH 2021
Venetoclax: undetectable peripheral blood MRD status as a therapeutic goal in R/R CLL
Venetoclax: undetectable peripheral blood MRD status as a therapeutic goal in R/R CLL
Profiling deep minimal residual disease in multiple myeloma
Profiling deep minimal residual disease in multiple myeloma
Analysis of GAIA/CLL13: the role of NGS-based MRD assessment after ven-based 1L combinations for CLL
Analysis of GAIA/CLL13: the role of NGS-based MRD assessment after ven-based 1L combinations for CLL
Multiomics Profiling of MRD for Understanding the Biology of Ultra-Drug Resistance in Myeloma
Multiomics Profiling of MRD for Understanding the Biology of Ultra-Drug Resistance in Myeloma